Woodline Partners’s United Therapeutics UTHR Stock Holding History

Woodline Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Buy	23,074 +19,597	+564%	+$11M	0.04%	482
2026 Q1	$2.06M	Buy	3,477 +2,692	+343%	+$1.34M	0.01%	803
2025 Q4	$382K	Sell	785 -2,662	-77%	-$1.24M	﹤0.01%	929
2025 Q3	$1.45M	Buy	+3,447	New	+$1.16M	0.01%	766
2024 Q1	–	Sell	-80,277	Closed	-$17.7M	–	639
2023 Q4	$17.7M	Buy	80,277 +69,353	+635%	+$16M	0.19%	165
2023 Q3	$2.47M	Sell	10,924 -95,247	-90%	-$21.9M	0.03%	381
2023 Q2	$23.4M	Buy	106,171 +39,348	+59%	+$8.72M	0.28%	105
2023 Q1	$15M	Buy	+66,823	New	+$16.5M	0.2%	143
2022 Q1	–	Sell	-36,211	Closed	-$7.82M	–	830
2021 Q4	$7.82M	Buy	+36,211	New	+$7.11M	0.11%	228

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Woodline Partners's UTHR Position: Q2 2026 in Review

Woodline Partners increased its United Therapeutics (UTHR) stake by 564% in Q2 2026, buying an estimated $11M and bringing the position to 23,074 shares worth $12.5M. The position accounts for 0.04% of the portfolio, ranked #482.

Woodline Partners first reported a position in UTHR in Q4 2021 and has held it in 9 quarters since. The position peaked at $23.4M in Q2 2023. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Woodline Partners held 23,074 shares of United Therapeutics worth $12.5M as of Q2 2026.
Woodline Partners bought 19,597 United Therapeutics shares in Q2 2026, an estimated $11M.
United Therapeutics made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #482 holding.
Woodline Partners first reported a position in United Therapeutics in Q4 2021 and has held it in 9 quarters since.
Woodline Partners's United Therapeutics position peaked at $23.4M in Q2 2023.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.